Inhibition of Selenoprotein I promotes ferroptosis and reverses resistance to platinum chemotherapy by impairing Akt phosphorylation in ovarian cancer
Jing Li, Mimi Chen, Dingwen Huang, Ziyin Li, Yu Chen, Jinhua Huang, Yuanqun Chen, Zhili Zhou, Zhiying Yu · 2024
Read Inhibition of Selenoprotein I promotes ferroptosis and reverses resistance to platinum chemotherapy by impairing Akt phosphorylation in ovarian cancer by Jing Li, Mimi Chen, Dingwen Huang, Ziyin Li, Yu Chen, Jinhua Huang, Yuanqun Chen, Zhili Zhou, Zhiying Yu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11635127.txt.
Description
Jing Li and co-authors probe a selenium-bearing protein that may help ovarian cancer resist key drugs. Their 2024 study scans many cancer types and finds the protein raised in most, with links to worse outlook and weaker immune attack. Lab tests then switch the protein off in ovarian cancer cells.
Switching it off stalled cell growth and curbed spread traits. It also pushed cells toward an iron-driven death and restored their response to a platinum drug. The path runs through a growth signal switch that the protein normally keeps on. In mice, blocking the protein shrank tumors and boosted drug effect. The authors pitch it as a target for hard-to-treat cases.
Catalog record
| CREATOR | Jing Li, Mimi Chen, Dingwen Huang, Ziyin Li, Yu Chen, Jinhua Huang, Yuanqun Chen, Zhili Zhou, Zhiying Yu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |